Targeted Protein Degradation (TPD) refers to the use of bifunctional small molecule Degraders, such as PROTACs™, to achieve proteasomal degradation of a target protein by harnessing the intracellular ubiquitin proteasome system. These compounds can be used to investigate the downstream effects of protein knockdown, or to investigate specific signaling pathways in health and disease.
This webinar introduces the topic of TPD, discusses the optimization of rational design of Degrader compounds, and highlights the dTAG platform for cellular target validation.
- The ubiquitin proteasome system
- Structure and chemistry of bifunctional small molecule Degraders
- Protein degradation in drug discovery
- The dTAG system for target validation
About the Presenters
William Farnaby is currently a team leader in medicinal chemistry and chemical biology, at the School of Life Sciences, University of Dundee. His multi-disciplinary team aims to develop next generation Degraders that will address unmet therapeutic needs.
Behnam Nabet, Ph.D. is a research fellow in the Dana-Faber Cancer Institute, MA, USA. Working within the lab of Nathanael Gray, Dr Nabet is developing a generalizable technology platform, the dTAG system, to rapidly degrade any protein of interest by combining Degrader chemistry with genome engineering.
PROTAC is a trademark of Arvinas, Inc.